Efficacy and Safety of Topical Pidobenzone 4% as Adjuvant Treatment for Solar Lentigines: Result of a Randomized, Controlled, Clinical Trial

  • Dermatology. 2016;232(4):478-83. doi: 10.1159/000447356.
Anna Campanati  1 ,  Melania Giannoni ,  Alessandro Scalise ,  Simona De Blasio ,  Angela Giuliano ,  Katia Giuliodori ,  Giulia Ganzetti ,  Elisa Bolletta ,  Giovanni Di Benedetto ,  Annamaria Offidani
Affiliations
  • 1. Dermatology Unit, Department of Clinical and Molecular Medicine, Marche Polytechnic University, United Hospitals, Ancona, Italy.
PMID: 27513344 DOI: 10.1159/000447356
Abstract

Background/objective: This study aims at the evaluation of the efficacy and safety of a combination therapy based on pidobenzone 4% and fractional CO2 laser or cryotherapy in the treatment of solar lentigines and the prevention of eventual posttreatment hyperchromia.

Methods: Efficacy was clinically evaluated by grading the pigmentation level with the Skin Tone Color Scale (STCS), and by grading patients' impression through a Visual Analog Scale (VAS).

Results: Our study shows that the associated treatment was safe and that it improves the therapeutic results on solar lentigines and prevents postiatrogenic hyperpigmentation compared with physical therapy alone.

Conclusion: The combination of cryotherapy and pidobenzone 4% has been found to be the most useful treatment.

Products